BeiGene
BGNE
£140.03
Share price
0.49%
Change (1 day)
26.04%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
EPS for BeiGene (BGNE)
EPS in 2023 (TTM): -£13.93
According to BeiGene 's latest financial reports the company's current EPS (TTM) is -£12.62. In 2022 the company made an earnings per share (EPS) of -£14.68 a decrease over its 2021 EPS that were of -£11.53.
EPS history for BeiGene from 2015 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -£13.93 | -5.13% |
| 2022 | -£14.68 | 27.35% |
| 2021 | -£11.53 | -19.96% |
| 2020 | -£14.41 | 20.81% |
| 2019 | -£11.93 | 31.52% |
| 2018 | -£9.07 | 417.57% |
| 2017 | -£1.75 | -37.16% |
| 2016 | -£2.79 | 158.95% |
| 2015 | -£1.08 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 | -£0.76 | -93.99% | 🇺🇸 USA |
 | -£0.20 | -98.38% | 🇺🇸 USA |